Haploinsufficiency of Activation-Induced Deaminase for Antibody Diversification and Chromosome Translocations both In Vitro and In Vivo by Sernández, Isora V. et al.
Haploinsufficiency of Activation-Induced Deaminase for
Antibody Diversification and Chromosome
Translocations both In Vitro and In Vivo
Isora V. Serna ´ndez
1, Virginia G. de Ye ´benes
1, Yair Dorsett
2, Almudena R. Ramiro
1*
1DNA Hypermutation and Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain, 2The Rockefeller University, New York, New York, United States
of America
Abstract
The humoral immune response critically relies on the secondary diversification of antibodies. This diversification takes
places through somatic remodelling of the antibody genes by two molecular mechanisms, Class Switch Recombination
(CSR) and Somatic Hypermutation (SHM). The enzyme Activation Induced Cytidine Deaminase (AID) initiates both SHM and
CSR by deaminating cytosine residues on the DNA of immunoglobulin genes. While crucial for immunity, AID-catalysed
deamination is also the triggering event for the generation of lymphomagenic chromosome translocations. To address
whether restricting the levels of AID expression in vivo contributes to the regulation of its function, we analysed mice
harbouring a single copy of the AID gene (AID
+/2). AID
+/2 mice express roughly 50% of normal AID levels, and display a mild
hyperplasia, reminiscent of AID deficient mice and humans. Moreover, we found that AID
+/2 cells have an impaired
competence for CSR and SHM, which indicates that AID gene dose is limiting for its physiologic function. We next evaluated
the impact of AID reduction in AID
+/2 mice on the generation of chromosome translocations. Our results show that the
frequency of AID-promoted c-myc/IgH translocations is reduced in AID
+/2 mice, both in vivo and in vitro. Therefore, AID is
haploinsufficient for antibody diversification and chromosome translocations. These findings suggest that limiting the
physiologic levels of AID expression can be a regulatory mechanism that ensures an optimal balance between immune
proficiency and genome integrity.
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Introduction
B cells are responsible for generating a repertoire of antibodies
of virtually unlimited diversity in order to confront the antigenic
universe. Antibody diversification is achieved through somatic
remodelling of immunoglobulin (Ig) genes at two different stages of
B cell differentiation. The first one is antigen- independent and
takes place during B cell generation in the bone marrow through a
site-specific recombination named V(D)J recombination, which
gives rise to B cells expressing a primary repertoire of Iow affinity
IgM antibodies (reviewed in [1]). Upon antigen encounter B cells
have as yet another chance to further diversify their antibody
repertoire in germinal centers by two independent molecular
mechanisms called somatic hypermutation (SHM) and class switch
recombination (CSR). SHM reshapes the antigen binding site of
Igs by introducing nucleotide changes in their variable genes. B
cells where SHM gives rise to antibodies with higher affinity for
their cognate antigen are positively selected, a process referred to
as affinity maturation (reviewed in [2] and [3]). CSR is a region-
specific recombination reaction that replaces the primary m
constant (Cm) region by a downstream constant region (Cc,C e
or Ca), thereby generating antibodies endowed with new functions
for pathogen neutralization while retaining the same antigen
specificity. CSR takes place between highly repetitive sequences
that precede the Cm,C c,C e and Ca genes, called switch regions,
through the generation of double strand breaks (DSBs), ligation,
and concomitant excision of the intervening sequence from the
locus (reviewed in [4,5]).
Both SHM and CSR are initiated by the very same enzyme,
Activation Induced Cytidine Deaminase (AID) [6]. In humans,
mutations in the AID gene are associated with a rare (1/2000000)
immunodeficiency called Hyper IgM Syndrome type 2 (HIGM2)
[7]. HIGM2 patients display impaired CSR and SHM and are
prone to bacterial infections of the respiratory and digestive tracts
[7]. AID initiates SHM and CSR by deaminating cytosine residues
of the variable and switch regions of the Ig genes, respectively
[8,9,10,11,12,13]. Cytosine deamination on DNA converts a
normal C:G pair into a U:G mismatch. AID-generated U:G
mismatches are processed through uracil removal by Uracil-N-
Glycosylase (UNG) or through recognition by the mismatch repair
(MMR) machinery, which results in the generation of either a
mutation (SHM) or a DSB (CSR) [11,14,15,16].
Most of the lymphomas diagnosed in the western world arise
from mature B cells and are characterized by the presence of
chromosomal translocations that involve one of the Ig loci and a
proto-oncogene [17,18]. These translocations are known to play a
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vitro studies have shown that AID can promote the generation of
pro-lymphomagenic translocations [19,20,21,22], and that CSR
and the translocation reaction are initiated by a common pathway
that involves DNA deamination and UNG [20]. The impact of
AID function in B cell neoplasia development has been addressed
in a number of in vivo models, including IL6 [19,21] and pristane
[23] promoted plasmacytomas, BCL-6-induced diffuse large B cell
lymphoma [22], Em-Myc model of B cell lymphoma [24] and a
myc-induced multiple myeloma model [25]. In all the cases
absence of AID either delayed the onset or shifted the nature of
the neoplasia towards a more immature origin, hence reinforcing
the idea that AID expression plays a role in the generation of
mature B cell lymphomas by promoting DNA lesions.
Therefore, AID function, while crucial to the development of an
efficient immune response, can pose a risk to DNA stability in B
cells. Different regulatory mechanisms may be responsible to
minimize unwanted DNA damage by AID.
First, AID mutagenic activity is mostly limited to the Ig loci
(reviewed in [26]), and although AID-induced lesions in other
genes have been reported [27,28], these events are rare. Second,
AID accessibility to DNA is restrained by fine control of
subcellular localization [29,30]. Third, the presence of AID
mRNA is mainly restricted to activated mature B cells [31], thus
limiting its function to the cell type and time window where it is
required. Transcriptional regulation exerted by B cell specific
transcription factors and cis elements (reviewed in [32], as well as
microRNA-mediated post-transcriptional regulation [33,34,35]
contribute to this expression pattern.
We hypothesized that limiting physiological AID expression
levels could provide an additional mechanism to restrict its
deleterious activity. To address this question we analysed the
impact of AID reduction in AID
+/2 mice on CSR, SHM and the
generation of chromosome translocations.
Results
AID expression is limiting for its function in CSR
In order to assess whether physiologic AID expression level is
limiting for its function, we evaluated AID gene dose effect in mice
harbouring one or two functional alleles of the AID gene, AID
+/2
and AID
+/+ mice, respectively. B cells from congenic Balb/c ByJ
animals [21] were used to minimize strain-to-strain variations. We
first wanted to ascertain that deletion of one AID allele in AID
+/2
mice resulted in a reduction of AID levels as compared to AID
+/+
mice. Mature B cells were isolated from spleens from AID
+/+ and
AID
+/2 mice, stimulated in vitro in the presence of LPS and IL4 to
promote AID transcriptional activation, and AID expression was
quantified after 3 days of culture by real-time RT-PCR. We found
that indeed AID mRNA levels are reduced roughly to 50% in
AID
+/2 as compared to wild type AID
+/+ B cells (Figure 1a). AID
deficient mice display a mild B cell hyperplasia and enlarged
germinal centers [6]. We found that AID
+/2 mice have slightly
increased numbers of B cells in spleen as compared to AID
+/+
(Figure 1b) and contain a higher proportion of germinal center B
cells in Peyer’s patches, as measured by the expression of the
GL7
+Fas
+ activation markers (Figure 1c).
The above results indicate that AID
+/2 cells express reduced
levels of AID mRNA and show hyperactivation features that are
intermediate between AID proficient (AID
+/+) and AID deficient
(AID
2/2) cells.
To address if reduced AID expression in AID
+/2 B cells results
in a decrease of serum Ig levels, we immunized AID
+/+, AID
+/2
and AID
2/2 mice with NP-CGG and analysed Ig concentration
by ELISA. In agreement with previously reported data [6], we
found no significant difference in serum Ig concentration between
heterozygous and fully deficient AID mice (Figure 1d), presumably
due to the high variablity in Ig titers. This result is consistent with
the finding by Takizawa et al that decreased Ig titers in immunized
AID
+/2 mice is only detected for antigen-specific high affinity
antibodies [36]. To directly measure the impact of AID reduction
on the induction of CSR, B cells isolated from AID
+/+, AID
+/2
and AID
2/2 spleens were stimulated in the presence of LPS and
IL4 to promote CSR to IgG1. FACS analysis after 2 days of
stimulation showed that AID
+/2 B cells show a reduction in the
efficiency of CSR to IgG1 (Figure 1e) which parallels the observed
reduction of AID mRNA levels (Figure 1a). CSR reduction in
AID
+/2 compared to AID
+/+ B cells can be observed throughout
the duration of the culture (Figure 1f) both for IgG1 isotype
(LPS+IL4 stimulation, graph on the left) and for IgG3 isotype (LPS
stimulation, graph on the right), and was not associated with
proliferation defects (Figure 1e and not shown).
We next asked if surpassing the level of physiologic AID
expression would conversely result in an increase of CSR. To
approach this issue we transduced spleen B cells from wild type
mice with retroviruses encoding AID or AID
E58Q catalytically
inactive mutant, together with GFP for tracking purposes. We
found that AID, but not AID
E58Q overexpression, promotes an
increase in the efficiency of CSR, as measured by the expression of
IgG1 after stimulation in the presence of LPS and IL4 (Figure 1g
and h).
From these results we conclude that AID gene dose affects the
efficiency of CSR in primary B cells, which implies that the AID
gene is haploinsufficient for CSR.
AID expression is limiting for SHM
To assess whether AID haploinsufficiency was also evident on
its activity in SHM we first analysed the accumulation of
mutations in the 59 end of the m switch region (Sm). AID activity
during CSR leads to the introduction of mutations in Sm.W e
stimulated CFSE-labelled spleen B cells from AID
+/+ and AID
+/2
mice in the presence of LPS and IL4 for 96h and quantified the
accumulation of mutations in cells that had undergone 5 or more
divisions after sorting, DNA extraction, PCR amplification,
cloning and sequencing. We found a lower mutation frequency
in the Sm region of AID
+/2 when compared to AID
+/+ cells
(1.2610
24 vs 1.9610
24) although this difference was not
statistically significant (t test p=0.171) (Figure 2a). We next
examined the SHM frequency in vivo by isolating Fas
+GL7
+
germinal centre cells from AID
+/2 and AID
+/+ peyer’s patches
and sequencing of the intronic region immediately downstream of
the JH4 gene. Our analysis showed that B cells from AID
+/2 mice
contain fewer mutations than AID
+/+ cells (0.9610
23 vs 3.1610
23
t test p=0.011) (Figure 2b). From these results we conclude that
AID is also haploinsufficient for SHM and therefore that the
physiologic level of AID expression is limiting for the diversifica-
tion of antibodies.
B cells from IL6tgAID
+/2 hyperplastic lymph nodes
harbour fewer translocations than IL6tgAID
+/+ B cells
IL6 transgenic (IL6tg) mice develop lymphoid hyperplasia,
presumably resulting from IL6-induced proliferation protection of
mature B cells from apoptosis. Hyperplastic lymphoid tissues from
IL6tg mice are enriched in B cells that harbour chromosomal
translocations involving the IgH locus and the c-myc proto-
oncogene (c-myc/IgH), analogous to those found in human
Burkitt lymphoma. In the absence of AID, IL6tg B cells are devoid
of c-myc/IgH translocations and the onset of lymphoid hyperpla-
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found in IL6tg mice cluster in a narrow region of the c-myc gene,
which encompasses part of its first exon and first intron. In
contrast, translocation breakpoints have been found spreading
over a large region of the IgH locus, from the V-JH region to the
alpha switch (Sa), which precedes the most distal alpha constant
(Ca) segment [19,21,37]. This distribution likely reflects the sites of
AID-initiated double strand breaks during CSR and on occasion,
during SHM.
To determine if AID gene dose has an influence on the
frequency or distribution of c-myc/IgH translocations in vivo we
analysed B cells from IL6tgAID
+/+ and IL6tgAID
+/2 hyperplastic
lymph nodes by long-range PCR, cloning and sequencing.
Oligonucleotides priming at the mu switch (Sm) region or at the
Sa region of the IgH were combined with c-myc oligonucleotides
to detect proximal, c-myc/IgHm or distal, c-myc/IgHa, translo-
cations, respectively [38] (Figure 3a). We found that the total
frequency of c-myc/IgH translocations was reduced in IL6t-
gAID
+/2 (0,77610
24) B cells when compared to IL6tgAID
+/+
(1,95610
24) (Figure 3c, left).
We readily detected proximal c-myc/IgHm translocations in
both IL6tgAID
+/+ and IL6tgAID
+/2 B cells, in agreement with
previous reports [21,37] (Figure 3b). When the frequency of c-
myc/IgHm translocations was calculated by performing serial
dilutions of B cell samples from hyperplasic lymph nodes, we
found that it was slightly reduced in IL6tgAID
+/2 when compared
with IL6tgAID
+/+ cells (Figure 3c, middle; 1.2610
24 vs
0.8610
24). Breakpoints from IL6tgAID
+/+ and IL6tgAID
+/2
translocations were mapped and characterized by cloning and
sequencing (Figure 3d and Table 1). We found that translocation
breakpoints at the c-myc gene mostly clustered at the end of the
first exon and the beginning of the first intron, regardless of the
genotype being analysed (Figure 3d). Breakpoints at the IgH locus
Figure 1. AID is haploinsufficient for CSR. (A) AID levels are
reduced in AID
+/2 mice. Spleen B cells from AID
+/+, AID
+/2 and AID
2/2
were stimulated for 3 days in the presence of LPS and IL4. RNA was
isolated and AID expression was assessed by real-time RT-PCR. Bars
represent AID mRNA expression relative to AID
+/+ B cells. Statistical error
bars show standard deviation (n=5). ND, non-detectable. (B) AID
+/2
spleens contain increased numbers of B cells. Bars represent the number
of spleen B cells (CD43 negative) and statistical bars represent standard
deviations. n (AID
+/+)=18, n (AID
+/2)=16 and n (AID
2/2)=9. t test p
(AID
+/+ vs AID
+/)=6 610
24. (C) Peyer’s patch B cells from AID
+/2 mice
contain intermediate Fas
+GL7
+ cell numbers. Spleen B cells from AID
+/+,
AID
+/2 and AID
2/2 were stained with anti-Fas and anti-GL7 antibodies
and analysed by flow cytometry. Percentage of Fas
+GL7
+ cells is
indicated. One representative experiment is shown (n=3). (D) ELISA
quantification of IgG serum levels in AID
+/+ (n=5), AID
+/2 (n=5) and
AID
2/2 (n=3) mice 15 days after NP-CGG (black bars) or PBS (white bars)
injection. Statistical bars represent standard deviations. (E) CSR efficiency
is reducedin AID
+/2 B cells. Spleen B cellsfromAID
+/+,AID
+/2 andAID
2/2
were stimulated for 3 days in the presence of LPS and IL4. CSR to IgG1
was measured by flow cytometry. Representative plots of CFSE labelling
and IgG1 expression are shown. Percentage of IgG1
+ cells is indicated. (F)
Time-course analysis of CSR. B cells from AID
+/+,A I D
+/2 and AID
2/2 were
stimulated for the indicated times (X axis) in the presence of LPS and IL4.
Percentage of IgG1
+ as measured by flow cytometry is represented
(Y axis). Statistical bars show standard deviations. p values (AID
+/2 vs
AID
+/+) for IgG1: 48h, 0.04; 72h, 0.03; 96h, 6610
23; 120h, 3610
23;f o r
IgG3: 48h, 0.1; 72h, 8610
23; 96h, 0.02; 120h, 0.02 (unpaired two-tailed
Student’s t test, n=9). (G–H) AID overexpression increases CSR. Spleen B
cells from AID
+/+ mice were transduced with retroviral vectors encoding
wild type (AID) or a catalitically inactive (AID
E58Q) AID along with GFP to
monitor transduction. CSR to IgG1 was measured by flow cytometry 2
daysaftertransduction.(G)Arepresentativeflowcytometryplot isshown
in panel G. Percentages of IgG1
+ cells within the GFP
+ population are
shown. (H) Percentage of IgG1
+ cells within AID or AID
E58Q GFP
+ cells
determined in 4 independent experiments. Statistical bars represent
standard deviations. Statistically significant differences (p,=0.05) are
indicated with a (*) (A–H).
doi:10.1371/journal.pone.0003927.g001
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+/+ B
cells (Figure 3d), although this difference was not statistically
significant. Both mutation frequency nearby translocation junc-
tions and number of microhomology nucleotides at junctions were
similar in IL6tgAID
+/+ and IL6tgAID
+/2 B cells.
In contrast to c-myc/IgHm proximal translocations, we found
that distal c-myc/IgHa translocations, while present in 20% of the
IL6tgAID
+/+ samples, were not detected in any of the IL6tgAID
+/2
mice analysed (Figure 3b–c, right). We conclude that in vivo, the
reduction of AID expression in IL6tgAID
+/2 mice results in a
shifted pattern and reduced frequency of c-myc-IgH translocations.
The frequency of c-myc/IgH translocations generated in
vitro is reduced in AID
+/2 B cells
Lymphoid hyperplasia generated in IL6tg mice is a long latency
disease presumably involving complex selective events which can
bias the number and nature of the translocations found in sick
animals. In order to assess more faithfully the effect of limiting
AID gene dose on the generation of chromosomal translocations,
we analysed the frequency of these events as generated after short
in vitro cultures of primary B cells. C-myc/IgH translocations are
initiated in B cells through the same molecular pathway as CSR,
which involves cytosine deamination by AID, and UNG. This
process can be recapitulated in vitro by stimulating spleen B cells in
the presence of LPS and IL4. The frequency of these events in wild
type B cells is extremely low (below one translocation every ten
million cells), but it is increased in the absence of p53, p19
ARF or
ATM, reflecting that DNA damage and oncogenic stress pathways
are activated downstream of AID function to prevent aberrant
joinings or spreading of cells that harbour lymphomagenic
translocations. In particular, p53-mediated protection against
AID-triggered c-myc/IgH translocations seems to require both
alleles of the tumor suppressor, since p53
+/2 B cells display a
dramatic increase in translocation frequency when compared to
wild type littermates. Therefore we decided to exploit the higher
frequency of c-myc/IgH translocations found in p53
+/2 B cells to
determine whether restricting AID expression levels has an impact
on the occurrence of these events.
To verify that the p53
+/2 genotype or the mixed strain of these
mice do not interfere with AID haploinsufficiency (described
above), we generated p53
+/2AID
+/+ and p53
+/2AID
+/2 animals
and analysed the efficiency of CSR in LPS+IL4 B cell cultures.
Expectedly, we found that p53
+/2AID
+/2 B cells show a
decreased level of CSR when compared to p53
+/2AID
+/+ cells,
as measured by the expression of IgG1 at different culture time-
points (Figure 4a). This reduction is comparable to that observed
in Balb/c p53
+/+ mice (see above).
Translocation frequency was then assessed in p53
+/2AID
+/+
and p53
+/2AID
+/2 spleen B cells upon LPS+IL4 activation.
Spleen B cells were isolated from 10 independent mice (5 mice per
genotype), and the presence of translocations was analysed by
PCR (depicted in Figure 3a, left) in 90 million cells (45 million cells
per genotype) after 3 days of stimulation. Translocation identity
was verified after gel analysis, southern blot with IgH- and myc-
specific probes (see Figure 4b for representative gels), cloning, and
sequencing. We found that the frequency of c-myc/IgH
translocations is significantly reduced in p53
+/2AID
+/2 B cells
as compared to p53
+/2AID
+/+ (0,19610
26 vs 0,61610
26, Fisher
test p=0,0025). We did not find significant differences regarding
translocation breakpoints (mapped in Figure 4d), mutations or
microhomology at junctions (Table 2) in p53
+/2AID
+/2 vs p53
+/2
AID
+/+ translocations.
From this result we conclude that the reduced AID levels
expressed by mice that harbour a single copy of the gene (AID
+/2)
results in a decreased frequency of c-myc/IgH translocations.
Therefore, AID is haploinsufficient for the generation of these
lymphomagenic lesions.
Discussion
The progress of the humoral immune response relies on the
reshaping of the antibody repertoire upon infection by the
introduction of somatic changes into the DNA of Ig genes. Higher
affinity antibodies are produced by SHM and new effector
capabilities are generated by CSR. SHM and CSR are initiated by
AID through the deamination of cytosine residues on antibody
genes [6]. Accordingly, AID is a critical enzymatic activity for the
development of the adaptive immune response [6,7]. Recent
reports have stated that AID-mediated deamination on DNA can
also lead to the generation of unwanted lesions, namely, mutations
outside the Ig genes [27,28], or DNA breaks and chromosomal
translocations [19,20,21,22], whose contribution to lymphoid
neoplasia has been demonstrated in several in vivo models
[19,21,22,23,24,25]. Therefore AID function is expected to be
tightly regulated to prevent the generation of DNA lesions.
Figure 2. AID is haploinsufficient for SHM. (A) Sm mutation
frequency in AID
+/+ and AID
+/2 activated B cells. The Sm mutation
frequency was quantified in sorted CFSE-labelled spleen B cells that had
undergone 5 or more divisions after 96h of LPS and IL4 stimulation.
Segment sizes in the pie charts are proportional to the number of Sm
sequences carrying the number of mutations indicated in the periphery
of the charts. The total number of independent sequences analyzed is
indicated in the center of each chart. The calculated mutation
frequency per base pair is indicated underneath. Statistical significance
was determined by a two-tailed Student’s t test comparing the
frequency found in AID
+/+ and AID
+/2 B cells. P values are indicated.
(B) SHM analyzed in the intronic region 39 of JH4 of germinal center B
cells from AID
+/+ and AID
+/2 mice. Segment sizes in the pie charts are
proportional to the number of mutations found in the intronic region 39
of JH4 of Fas
+GL7
+ sorted B cells from Peyer’s patches of aged-matched
AID
+/+ and AID
+/2 mice. The total number of independent sequences
analyzed is indicated in the center of each chart. The calculated
mutation frequency per base pair is indicated underneath. Statistical
significance was determined by a two-tailed Student’s t test comparing
the frequency of mutations found in AID
+/+ and AID
+/2 mice. P values
are indicated.
doi:10.1371/journal.pone.0003927.g002
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expression levels in vivo could play a regulatory role in its activity. We
performed our analyses in mice that harbour a single functional allele
of the AID gene, which results in a reduction of roughly 50% of AID
mRNA levels.This reduction islikely due to a per-cell decrease of AID
levels, as it has been shown that AID expression is biallelic [36].
Figure 3. c-myc/IgH translocation frequency is reduced in IL6tgAID
+/2 mice. (A) Schematic representation of the IgH and c-myc genes
(upper) and the derivative chromosomes (c-myc/IgHm and c-myc/IgHa, lower) arising from proximal and distal translocations, respectively. Variable
(VH) and constant (Cm and Ca) genes are represented as grey and black boxes, respectively. Sm and Sa switch regions and Em enhancer are shown as
striped and black ellipses, respectively. C-myc exons are drawn as white boxes. Arrows show the position of primers used for PCR amplification. (B)
Proximal (left) and distal (right) c-myc/IgH translocations detected in IL6tgAID
+/+ (upper gels) and IL6tgAID
+/2 (lower gels) mice. DNA from IL6tgAID
+/+
and IL6tgAID
+/2 hyperplastic lymph node B cells was amplified as described in materials and methods using the primers depicted in (A). Representative
amplification products analysed in ethidium bromide stained gels are shown. Mouse identifications are shown above the lanes. (C) Frequency of c-myc/
IgH translocations in IL6tgAID
+/+ and IL6tgAID
+/2 mice. Translocation frequency was determined by serial dilution of DNA samples, followed by PCR
amplification, cloning andsequencing. Graphs show the overall translocation frequency (left), frequency of proximal c-myc/IgHm translocations (middle)
and frequency of distal c-myc/IgHa translocations (right). (D) Representation of translocation breakpoints at the c-myc and IgHm genes found in
IL6tgAID
+/+ andIL6tgAID
+/2 B cells. Amplificationproductsof proximalc-myc/IgHtranslocationswere cloned andsequenced. Translocation breakpoints
at the c-myc (upper diagram) and IgH (lower diagram) genes are shown as closed (IL6tgAID
+/+) and open (IL6tgAID
+/2) circles. C-myc exon 1 and IgH Em
enhancer arerepresented as grey boxes and distance to these elements is shown underneath (bps). Arrows on the right indicate the position of the PCR
oligonucleotides used for amplification.
doi:10.1371/journal.pone.0003927.g003
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hyper IgM immunodeficiency syndrome that is characterized by
the absence of somatic mutations and of Ig isotypes other than
IgM. This phenotype is accompanied by lymphoid hyperplasia
and enlarged germinal centers. Although the significance of these
latter features to the immunodeficiency is unclear, we found that
reduction of AID expression in AID
+/2 mice brings about a mild
increase of B cell numbers in the spleen and of germinal center
cells in Peyer’s patches. More importantly, AID gene dose is
indeed limiting for the generation of switched isotypes, as B cells
from AID
+/2 mice have an impaired ability to perform CSR in
vitro, in agreement with very recently published results [36,39]
This observation is reinforced by the finding that exogenous AID
expression results in an increase of the CSR rate. In addition, our
results show that AID expression is also limiting for SHM.
Altogether these data indicate that AID is haploinsufficient for
antibody diversification. In humans, AID deficiency (HIGM2) is
considered an autosomal recessive disease [7,40,41,42]. This
apparent discrepancy with our data can be explained by the fact
that HIGM2 patients have relatively mild and variable clinical
phenotypes, possibly due to the contribution of genetic and
environmental factors [7,41,43]. Among those, it is important to
note that numerous different mutations in the AID gene have
been identified in HIGM2 patients, whose impact on the
efficiency of the CSR and SHM reactions is highly variable
[7,41,43,44]. In addition, the number of HIGM2 patients
characterised so far is small [45], which makes it very difficult
to establish genotype-phenotype relationships. Therefore, it is
expected that heterozygous individuals display mild to absence of
clinical manifestations.
Our analysis of AID-induced chromosomal translocations shows
that elimination of one AID allele reduces the frequency of these
aberrations. Of note, c-myc/IgH translocations involving the
distal Sa switch region were not detected in B cells from
IL6tgAID
+/2 hyperplasic lymph nodes. Although the sample size
does not allow concluding that this absence is absolute, our data
indicate that Sa translocations are very infrequent when the
amount of AID is limiting. This observation is in agreement with
the finding that the frequency of AID mutations in Sa is much
lower than in Sm [46]. In turn, this would imply that, in the
presence of a single AID allele, the lesions that trigger a DSB in
this region are very rare and fall below our detection limit.
Analysis of AID-promoted c-myc/IgH translocations in in vitro
stimulated B cells has allowed an accurate measurement of the
frequency of these events in AID
+/2 B cells, as opposed to the
IL6tg (this study) or pristane induced plasmacytomas in Bcl-xL
mice [36], where the contribution of in vivo selective mechanisms
can not be discriminated. Our results show unequivocally that
reduction of AID levels results in a significant decrease in the
frequency of these events. This reduction in c-myc/IgH
translocations found in AID
+/2 mice is not accompanied by a
shift in the location or nature of translocation breakpoints, which
indicates that diminishing AID levels affects only the frequency of
targeting, rather than its specificity.
Table 1. c-myc/IgH chromosomal translocations in IL6tg mice
Transloction
a ID
b Genotype c-myc
c Jnc
d IgH
e
IgHm A1 AID
+/+ AAACAGCTCGAGGAaCTCTTTTCAG G GCTGGGGTGAGCTGAGCTGAGCTGG
IgHm A2 AID
+/+ CTTTCCTCTGTCATCTTGACAAGTC CTGAGCTGGGTGAGCTGAGCTGAAC
IgHm A3 AID
+/+ GCCTTCAAACAGCTCGAGGAGCTCT CTGGATTGAACTGAGCTGTGTGAgC
IgHm A4-1 AID
+/+ AATCCAGCCTTCAAACAGCTCGAGG AGC CCTGCCTGCCTTAAGAGTAGCAACA
IgHm A4-2 AID
+/+ GGACGGGTTGCGATCGCCGCtGGGG TGAGCTGGGGTGAGCTGAGCTGGGG
IgHm A10 AID
+/+ TTGGGGAGAGTGGGCGGCAGGCTCG TGGGATGAGGTAGGCTGGGATGAGC
IgHm A11 AID
+/+ AGAGCTGATCGCGGGCAGAGGCAGA G GCTGGCCTGGCTGATGAGCTAAGCT
IgHm A13 AID
+/+ AGCCTGGGGAGTCCTGTCCTGGCTC GC TGGGGTGAGCTGAGCTGAGCTGAGC
IgHm A15 AID
+/+ TAAAAGGCTCAGGGACGGGTTGCGA GAGCTGAGCTGGGGTGAGCTGAGCT
IgHm A17 AID
+/+ ACTCTTGAGAAAAGTGTCAAAAaCA C TGGGGTGAGCTGAGCTGAGCTGAGC
IgHm B2 AID
+/2 CTAGCAATTCAGGGGCGCGAGGCAT A GCTGAGCTGAGCTGAGCTGGGTGAG
IgHm B5 AID
+/2 CTCTTGAGAAAAGTGTCAAAAGtAC A aCTGAGCTGAGCTGAGCTGGGGTGA
IgHm B6 AID
+/2 CACTCCAGAGCTGCCTTCTTAGGTC GC TGAGCTGGGGTGAGCTGGGCTGAGC
IgHm B7 AID
+/2 AAGAACACAGGGAAAGACCACCAGA GCTGGGGTGAGCTGAGCTGAGCTGG
IgHm B9 AID
+/2 TCAAAATGCATCCCGGTTTTTCCCT T GGGCTGAGCTGGGTTGGGAGACCAT
IgHm B10 AID
+/2 CTCTTTTCAGGAGAGCTGATCGCGG GC TGGGGTGAGgTGaGCTGAGCTGGGG
IgHm B11 AID
+/2 AAAGCACAGGAATGGAAGAAAGACT G CTGAGCTGGGGTGAGCTGAGCTGAG
IgHm B13 AID
+/2 CAAGAATGTCCAACCGGCCGGGTCA G AGCTGAGCTGGGGTGAGCTGAGCTG
IgHa A11 AID
+/+ ATCTTGACAAGTCGCTCTACCCCGA CT GAGCTAGACTTANGGTGNAATGGGC
IgHa A12 AID
+/+ GGGATTGGCGGGCGGGACGCACCTC C TAGgCTGGGGTGAATTAGCATGACT
IgHa A15 AID
+/+ AACCGGCCGCTACATTCNAGACGCA G CTGGGCTGAGCTGGAATGAGCTGGG
aProximal (IgHm) or distal (IgHa) c-myc/IgH chromosomal translocation.
bMouse identification as referred to in figure 2b.
cc-myc sequence adjacent to translocation junction. Mutations are shown in lowercase.
dMicrohomology at junctions (overlapping sequences that cannot be assigned to a single sequence, c-myc, or Ig).
eIgH Reverse complementary sequence adjacent to translocation junction. Mutations are shown in lowercase.
doi:10.1371/journal.pone.0003927.t001
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sion in primary B cells produces a major increase in the frequency
of c-myc/IgH translocations. In particular, a ten fold protein
increase gave rise to a thousand fold increase in translocation
frequency [20]. This observation suggests that surpassing a certain
level of AID expression is likely to overwhelm the cellular
surveillance pathways that protect against these lesions and to
result in their accumulation in a non-linear fashion. Together,
these results show that AID haploinsufficiency is also revealed in its
deleterious activity as promoter of illegitimate chromosome
fusions. Interestingly, previous results have shown a longer median
survival for IL6tgAID
+/2 than for IL6tgAID
+/+mice (7.9 vs 5.5
months) in two independent studies which showed similar survival
curves for IL6tgAID
2/2 mice [19,21]. Very recently it has been
reported that in a Bcl-xL transgenic background, AID
+/2 mice
have a delayed plasmacytoma development in response to pristane
injection [36]. Together, these observations indicate that AID
haploinsufficiency can be relevant for tumor progression in vivo.
In summary, we have found that a half reduction of AID
expression in mice harbouring a single AID allele, results in a
reduction of AID activity, both in the efficiency of antibody
diversification and in the frequency of generation of chromosome
translocations. This implies that there is a gene dose effect of AID
expression, and therefore, that AID is haploinsufficient. Our
findings suggest that restraining the physiologic levels of AID
expression can be a mechanism that allows the achievement of an
optimal balance between immune proficiency and genome
integrity.
Materials and Methods
Mice, B cell cultures, flow cytometry and ELISA assays
Congenic Balb/c AID
+/2 mice were obtained by breeding
Balb/c AID
2/2 mice (Ramiro et al., 2004) with wild type Balb/c
mice. p53
+/2AID
+/2 mice were obtained by breeding Balb/c
AID
2/2 mice with C57BL/6J p53
2/2 mice (Jackson laboratories).
Lymph node samples were obtained from IL6tgAID
+/+, IL6t-
gAID
+/2 and IL6tgAID
2/2 mice (Ramiro et al., 2004, Dorsett
2007). All experiments with mice were performed following the
Animal Bioethics and Comfort Committee protocols approved by
the Instituto de Salud Carlos III. B cells were purified from spleens
by anti-CD43 immunomagnetic depletion (Miltenyi Biotech),
labelled with 5 mm CFSE (Molecular Probes) (when indicated)
and cultured in RPMI in the presence of 25 mg/ml LPS (Sigma),
Figure 4. c-myc/IgH translocation frequency is reduced in activated AID
+/2 B cells. (A) p53
+/2AID
+/2 cells are haploinsufficient for CSR.
Spleen B cells from p53
+/2AID
+/+ and p53
+/2AID
+/2 were stimulated for the indicated times (X axis) in the presence of LPS and IL4. Percentage of
IgG1
+ as measured by flow cytometry is represented (Y axis). Statistical bars show standard deviations. p values (p53
+/2AID
+/2 vs p53
+/2AID
+/+) 48h,
0.7; 72h, 0.01; 96h, 6610
23; 120h, 0.03. (unpaired two-tailed t test, n=4). (B) Representative c-myc/IgH translocations detected in p53
+/2AID
+/+ and
p53
+/2AID
+/2 B cells. Spleen B cells from p53
+/2AID
+/+ and p53
+/2AID
+/2 mice were stimulated in vitro in the presence of LPS and IL4 for 3 days. DNA
was extracted and proximal translocations were amplified by PCR as depicted in Fig 2a (see materials and methods) and analysed in ethidium
bromide stained agarose gels (upper). Specificity of amplification products was determined by southern blot and hybridization with IgH (middle) and
myc (lower) probes. Results for p53
+/2AID
+/+ and p53
+/2AID
+/2 cells are shown on the left and right gels, respectively. Translocation identifications
are indicated above lanes. (C) Frequency of c-myc/IgH translocations in p53
+/2AID
+/+ and p53
+/2AID
+/2 B cells. Translocation frequency was
determined by serial dilution of DNA samples, followed by PCR amplification, cloning and sequencing. (D) Representation of translocation
breakpoints at the c-myc and IgHm genes found in p53
+/2AID
+/+ and p53
+/2AID
+/2 B cells. Amplification products of c-myc/IgH translocations were
cloned and sequenced. Translocation breakpoints at the c-myc (upper diagram) and IgH (lower diagram) genes are shown as closed (p53
+/2AID
+/+)
and open (p53
+/2AID
+/2) circles. C-myc exon 1 and IgH Em enhancer are represented as grey boxes and distance to these elements is shown
underneath (bps). Arrows on the right indicate the position of the PCR oligonucleotides used for amplification.
doi:10.1371/journal.pone.0003927.g004
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mercaptoethanol (Gibco) and 10% fetal bovine serum (Gibco). For
class switch recombination and differentiation assays BAFF
(20 ng/ml R&D Systems) was also included to the previously
described medium. Retroviral transductions were performed in
LPS+IL4 stimulated B cells in the presence of 8 mg/ml polybrene.
Flow cytometry analysis was performed after staining with anti-
GL7-FITC, anti-CD95-PE, anti-CD19-APC, anti-IgG1 biotin
and anti-IgG3 antibodies, APC-streptavidin and 7-AAD (all from
BD Biosciences) in a FACSCanto flow cytometer (BD Biosciences).
P-values were calculated using unpaired Student’s t test (Graph-
Pad software). For determination of serum Ig titers, age-matched
7–9 weeks old mice were immunized by footpad injection with
50 mg/ml of NP-CGG (Biosearch Technologies) in complete
Freund’s adjuvant. Serum was collected from blood samples 15
days after the immunization and IgG titers in AID
+/+, AID
+/2
and AID
2/2 mice were determined using a mouse IgG specific
ELISA system (Roche Applied Science).
Real time quantitative PCR
Total RNA was isolated with Trizol (Invitrogen) after Ficoll
gradient centrifugation (Amerham Biosciences) of stimulated B
cells and converted into cDNA using random primers (Roche) and
SuperScript II Reverse transcriptase (Invitrogen). AID mRNA was
quantified using SYBR Green assay (Applied Biosystems).
GAPDH amplifications were used as normalization controls.
Primers for AID were: 59-ACCTTCGCAACAAGTCTGGCT-
39and 59-AGCCTTGCGGTCTTCACAGAA-39. Primers for
GAPDH were: 59-TGAAGCAGGCATCTGAGGG-39and 59-
CGAAGGTGGAAGAGTGGGAG-39. Quantitative PCRs were
performed on 7900HT fast real-time PCR system (Applied
Biosystems). P-values were calculated using paired Student’s t test
(GraphPad software).
Mutation analysis
For analysis of mutations at the Sm region, CD43
2 spleen B cells
were CFSE labelled, stimulated for 96h in the presence of LPS and
IL4 and B cells that had undergone 5 or more cell divisions were
isolated by sorting (FACSAria). DNA was extracted and amplified
using the oligonucleotides 59-AATGGATACCTCAGTGGTT-
TTTAATGGTGGGTTTA-39 and 59-GCGGCCCGGCTCA-
TTCCAGTTCATTACAG-39y for 26 cycles (Pfu Ultra, Strata-
gene). For JH4 intron mutations, Fas
+GL7
+ cells were purified by
cell sorting (FACSAria), DNA was isolated and amplified with
oligonucleotides 59ACTATGCTATGGAC-39 and 59-CTGGA-
CTTTCGGTTTGGTG-39 for 9 cycles and then 59-GGTCAAG-
GAACCTCAGTCA-39 and 59-TCTCTAGACAGCAACTAC-39
for 21 cycles using Pfu Ultra (Stratagene). Amplification products
were purified, cloned and sequenced. Sequence analysis was
performed using Lasergene software. P-values were calculated
using unpaired Student’s t test (GraphPad software).
Translocations assays
C-myc/IgH translocation detection by PCR was performed as
previously described (Ramiro et al., 2004; Kovalchuk et al., 1997)
on 1 mg (for p53
+/2 samples) or 500-4 ng (for IL6tg samples) of
genomic DNA. C-myc/IgHm and c-myc/IgHa translocations
were amplified using two rounds of PCR with Expand Long
Template PCR system (Roche). Primers for derivative 12 c-myc/
IgHm first round: 59-TGAGGACCAGAGAGGGATAAAAGA-
GAA-39 and 59-GGGGAGGGGGTGTCAAATAATAAGA-39;
for derivative 12 c-myc/IgHm second round: 59-CACCCTGC-
Table 2. c-myc/IgH chromosomal translocations generated in vitro
Transloction
a ID
b Genotype c-myc
c Jnc
d IgH
e
IgHm 1F7 AID
+/+ AGACTGTCCTAACCGGCCGCTACAT T GAGCTGAGCTGGGGTGAGCTGAGCT
IgHm 1G5 AID
+/+ AGACAAAAATTCCCTCCCCGGAGCC TG AGCTGGGTGAGCTGAGCTGGGGTGA
IgHm 2G7 AID
+/+ CCGCGGATCCCAAGTAGGAATGTaA GG GGTGAGCTGGGGTGAGCTGAGCTGA
IgHm 6H5 AID
+/+ AAATTTTACTACGATCACTATTTTT TGAGCTGAGCTGGGGTGAGCTGAGC
IgHm 6H8 AID
+/+ GTCGGTCCCAGGCTGTCAGAAATGC TGAACTGAATGAGTTTCACCAGGCC
IgHm 8B6 AID
+/+ AATGTCCAACCGACCGGGTCAGCGT GTGAGCTGAGCTGAGCTAGGGTGAG
IgHm 10G5 AID
+/+ ACCGGGGTTTCCAACGCCCAAAGGA GCTGAGCTGGGCTGAGCTGGGGTGA
IgHm 10G12 AID
+/+ ACAGCTCGAGGAGCTCTTTTCAGct GAGCTGA GCTGAGCTGAGCTGAGCTGAGCTGG
IgHm 10H5 AID
+/+ GGTTTCCCCCAAGTCAACGAATCGG T GAGCTGaGcTGgGgTGAGCTGAGCT
IgHm 11F4 AID
+/+ AACAGCTCGAGGAGCTCTTTTCAGc TGAGCTGAGCtGAGCTGAGCTGAGC
IgHm 11H7 AID
+/+ GAAATGCACCAAGCTGAAATTTAAA GGGGTGAGCTGAGCTAGGGTGAACT
IgHm 3C9 AID
+/2 GTCGGTCCCAGGCTGTCAGAAACGC TGAGCTTgGCTGAGCTAGgGTGAGC
IgHm 7D3 AID
+/2 AGTAACCTCGGGAACCCCGCTTCAA TGAGCTGgGgTGAGCTGaGCTGAGC
IgHm 8G5 AID
+/2 TCTTTTCAGGAGAGCTGATCGCGGG TGAGCTGAGCTGAGCTGGGGTGAGC
IgHm 8H10 AID
+/2 AGCTCTTTTCAGGAGAGCTGATCGC GGG TGAGCTGAGCTGAGCTGGGGTGAGC
IgHm 9A4 AID
+/2 AGTAACCTCGGGAACCCCGCTTCAA TGAGCTGGGGTGAGCTGAGCTGAGC
IgHm 9C3 AID
+/2 TGAGAAAAGTGTCAAAAGCACAaGA A GCTGAGCTGAGCTGGGGTGAGCTGg
IgHm 10A10 AID
+/2 GAGAGCTGATCGCGGGCAGAGGCAG GAGCTGGAG-TGAGCTGAGCTGGGCT
aProximal IgHm c-myc/IgH chromosomal translocation.
bMouse identification as referred to in figure 2b.
cc-myc sequence adjacent to translocation junction. Mutations are shown in lowercase.
dMicrohomology at junctions (overlapping sequences that cannot be assigned to a single sequence, c-myc, or Ig).
eIgH Reverse complementary sequence adjacent to translocation junction. Mutations are shown in lowercase.
doi:10.1371/journal.pone.0003927.t002
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TACACTCTAAACCG-39; for derivative 12 c-myc/IgHa first
round: 59-CGTGAATCAGGCAGCCGATTATCAC-39 and 59-
GGGGAGGGGGTGTCAAATAATAAGA -39; for derivative 12
c-myc/IgHa second round: 59-GAGCTGACCAACAGTT-
CTGGCTGTATAGAC-39 and 59-GACACCTCCCTTCTA-
CACTCTAAACCG -39. PCR products were purified, cloned
and sequenced. Translocation sequences were aligned using
SeqMan from Lasergene software. PCR products were separated
on agarose gels and denatured for 20 min in 0.4M NaOH before
transfer to nylon membranes and probed with c-P
32-ATP labelled
oligonucleotides (IgH probe: 59-CCTGGTATACAGGAC-
GAAACTGCAGCAG-39 and c-myc probe: 59- GCAGCGATT-
CAGCACTGGGTGCAGG-39). P-values were calculated using
two-tail Fisher’s test (GraphPad software).
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